Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.

Prostate growth curves were estimated from serial prostate-specific antigen (PSA) measurements on frozen sera in three groups of men: (a) 16 men with no prostatic disease by urological history and examination; (b) 20 men with a histological diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and (c) 18 men with a histological diagnosis of prostate cancer. The median number of repeated PSA measurements over an 8- to 26-yr period prior to histological diagnosis or exclusion of prostate disease was eight and 11 for noncancer and cancer subjects, respectively. Predicted rates of change in PSA (PSA velocity) were linear and curvilinear for control and BPH subjects, respectively. Subjects with cancer demonstrated both a linear and an exponential phase of PSA velocity. Based on time to double PSA, we estimated the epithelial doubling time for men without prostate disease to range from 54 +/- 13 yr at age 40 to 84 +/- 13 yr at age 70. For men with BPH, doubling times ranged from 2 +/- 13 yr at age 40 to 17 +/- 5 yr at age 85. Subjects with local/regional and advanced/metastatic cancer had similar PSA doubling times of 2.4 +/- 0.6 yr and 1.8 +/- 0.2 yr, respectively. These data are consistent with what is known about prostatic growth with age in men without prostate disease and BPH, and the kinetics of prostate cancer growth. Estimates of prostatic growth rate from changes in PSA may be useful clinically in management of men with prostate disease.

[1]  J. Meyer,et al.  Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. , 1982, The Journal of urology.

[2]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. , 1989, The Journal of urology.

[3]  I. Rossman,et al.  Normal Human Aging: The Baltimore Longitudinal Study of Aging , 1986 .

[4]  N. Kyprianou,et al.  Therapeutic Approaches to Activating Programmed Cell Death of Androgen-Independent Prostatic Cancer Cells , 1991 .

[5]  D. Bates,et al.  Newton-Raphson and EM Algorithms for Linear Mixed-Effects Models for Repeated-Measures Data , 1988 .

[6]  D. Bates,et al.  Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.

[7]  J. Oesterling,et al.  The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. , 1989, The Journal of urology.

[8]  E. Metter,et al.  Symptoms and signs of prostatism as risk factors for prostatectomy , 1990, The Prostate.

[9]  H. Kressel,et al.  Age-related changes of the prostate: evaluation by MR imaging. , 1989, AJR. American journal of roentgenology.

[10]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[11]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[12]  N. Juul,et al.  Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. , 1988, Scandinavian journal of urology and nephrology. Supplementum.

[13]  J. McNeal,et al.  Pathology of benign prostatic hyperplasia. Insight into etiology. , 1990, The Urologic clinics of North America.

[14]  David Arenberg,et al.  Normal Human Aging: The Baltimore Longitudinal Study on Aging , 1984 .

[15]  H A Guess,et al.  Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia , 1990, The Prostate.